azd8529
Small moleculeexperimental
Clinical trial activity
7 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2008 (NCT00755378)
Timeline
Indications
Mechanism of action
- Metabotropic glutamate receptor 2POSITIVE ALLOSTERIC MODULATOR
GRM2 positive allosteric modulator
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- azd8529
- azd8529
- azd 8529
- azd 8529
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02401022 | Phase 2 | Jul 1, 2015 | National Institute on Drug Abuse (NIDA) |
| NCT00985933 | Early Phase 1 (Phase 1) | Feb 1, 2010 | AstraZeneca, Yale University |
| NCT00986531 | Phase 1 | Nov 1, 2009 | AstraZeneca, University of Pennsylvania |
| NCT00921804 | Phase 2 | Jun 1, 2009 | AstraZeneca, CBH Health |
| NCT00886756 | Phase 1 | Apr 1, 2009 | AstraZeneca, Richmond Pharmacology |
| NCT00765492 | Phase 1 | Oct 1, 2008 | AstraZeneca |
| NCT00755378 | Phase 1 | Sep 1, 2008 | AstraZeneca |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 6 | 6 | 2 | 2008 |
| CBH Health | Academic/Hospital | 1 | 0 | 1 | 2009 |
| National Institute on Drug Abuse (NIDA) | Government | 1 | 1 | 1 | 2015 |
| Richmond Pharmacology | For profit | 1 | 0 | 1 | 2009 |
| University of Pennsylvania | Academic/Hospital | 1 | 0 | 1 | 2009 |
| Yale University | Academic/Hospital | 1 | 0 | 1 | 2010 |
6 organizations
Page 1 / 1